Life Edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties on global net product sales CAMBRIDGE, MA and DURHAM, ...

ElevateBio has enjoyed a close look at Life Edit Therapeutics over the past 11 months, with overlaps in the management team and involvement in its portfolio of cell and gene therapy companies giving ...

Novo Nordisk (NVO) has partnered with U.S.-based biotech Life Edit Therapeutics to discover and develop gene editing treatments targeted at rare and cardiometabolic diseases, the companies announced ...

Moderna Inc. MRNA announced Wednesday a collaboration agreement with privately held Life Edit Therapeutics Inc. to discover and develop in vivo gene editing therapies. Moderna’s stock edged up 0.4% in ...

DURHAM – Gene editing from a Durham-based firm that will target possible new therapeutics has led to a deal with international drug firm Novo Nordisk worth a potential $2 billion if not more. Life ...

In its bid to become, as Chairman and CEO David Hallal said, the “world’s most indispensable cell and gene therapy technology company,” Elevatebio LLC disclosed a $401 million series D round with ...

- Life Edit's genome editing capabilities to be fully integrated with ElevateBio's other cell and gene enabling technologies, including induced pluripotent stem cells (iPSCs), viral vector, and ...

Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities Multi-target collaboration to advance potentially ...